Although this disease has been known for 700 years, its cause remains unknown. Contrary to expectations, the development of fields such as molecular biology and immunology has made the situation even more complex.. Although more and more antibodies are being discovered that are associated with this disease, it turns out that they are not unique to this entity.
Systemic lupus erythematosus (SLE): conceptual framework, pathophysiological mechanisms, and immunological diagnostic complexities
Systemic lupus erythematosus (SLE) constitutes a complex, chronic autoimmune disorder characterized by systemic inflammation arising from dysregulated immune responses targeting the body’s own connective tissues. While patients with SLE consistently exhibit a broad array of autoantibodies—including antinuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA), anti-Smith (anti-Sm), and antiphospholipid antibodies—none of these markers demonstrate absolute specificity for the disease, thereby complicating definitive serological diagnosis. A pivotal observational milestone in unraveling the immunopathogenesis of SLE was the phenomenon of false-positive results in nontreponemal syphilis tests (e.g., VDRL), attributable to cross-reactivity between anticardiolipin antibodies and the lipid antigens employed in these assays. Persistence of such false-positive reactions for a minimum of six months may serve as a clinically significant indicator suggestive of SLE. Despite advances in identifying risk factors (genetic, environmental, hormonal) and elucidating the inflammatory cascade leading to organ damage, the etiopathogenesis of SLE remains incompletely understood. Contemporary medicine continues to seek answers to fundamental questions regarding the initiation of the disease process and its primary molecular and cellular underpinnings.
You have started reading a PRO article
You can preview the first chapter. To read the complete article and unlock all content, upgrade to a PRO account.